Robert Crofton has been a consultant with Syner-G for over 2 years. With 12 years of experience in the biopharmaceutical industry, he has worked in the manufacture and development of protein-based biologics, including downstream process development, analytical method development and validation, statistical analysis, and regulatory writing. He assisted writing the approved biologic license application for the drug RYPLAZIM, an orphan drug used to treat type I plasminogen deficiency.